Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

VIP interneuron impairment promotes in vivo circuit dysfunction and autism-related behaviors in Dravet syndrome.

Cell reports · 2023

Study scale: Briefly, neural data were divided into 1s chunks and randomly shuffled n=10000 times, then rn was recalculated for each cell in each shuffle to give a distribution of values rN.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Here, we investigate VIP-IN function at the circuit and behavioral level by performing in vivo 2-photon calcium imaging in awake wild-type (WT) and Scn1a+/− mice.

Study design

We used an established 2P calcium imaging paradigm to simultaneously assess the activity of VIP-INs and pyramidal neurons during behavioral-state transition in vivo.

Participants or experimental system

To validate that our results indeed reflected the activity of excitatory pyramidal neurons, we recorded from pyramidal cell-specific Slc17a7-Cre.WT mice injected with Cre-dependent GCaMP7s under otherwise identical conditions, thereby limiting GCaMP7s expression to a genetically identified excitatory neuron population.

Study scale

Briefly, neural data were divided into 1s chunks and randomly shuffled n=10000 times, then rn was recalculated for each cell in each shuffle to give a distribution of values rN.

Intervention or exposure

For 2P imaging experiments, VIP-INs from double transgenic Scn1a.VIP-Cre and WT.VIP-Cre littermates from the cross described above were labeled via stereotaxic injection of AAV9.pCAG.Flex.tdTomato.WPRE.

Comparator

Not reported in the declared source.

Outcomes examined

We tested this by injecting a low dose of the muscarinic agonist pilocarpine (10 mg/kg; typical convulsant doses are 300–400 mg/kg) and measured activity of individual cells within the same imaging field during both resting and locomotion epochs before and after pilocarpine injection (Figure 5A).

Key findings

Using in vivo 2-photon (2P) calcium imaging in awake mice, we found that patterns of activation of VIP-INs and pyramidal neurons associated with the onset of locomotion are attenuated in Scn1a+/− mice while SST-INs remain robustly activated.

Limitations and uncertainty

One important caveat of our experimental setup is that while tdT− non-VIP neurons predominantly represent excitatory neurons in layer 2/3, this may also include other non-VIP-IN populations including SST-INs, which may be differentially affected relative to pyramidal neurons by both loss of Scn1a and impairment of VIP-IN excitability.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles.

Neurochemical research · 2023

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Control, sham and nerve-lesioned animals were treated identically with nanoparticles.

Study scale

Not reported in the declared source.

Intervention or exposure

In one group of rats cerebrolysin (2.5 or 5 ml/kg, i.v.) was administered once daily after 2 weeks until sacrifice (4, 8 and 10 weeks).

Comparator

In sham group, the left spinal nerves L5 and L6 were exposed identically but not ligated.

Outcomes examined

In order to corroborate immunohistochemical studies, albumin, GFAP, myelin basic protein and HSP 72kD was measured in the spinal cord samples using Rat ELISA kits from MyBioSource (San Diego, CA, USA) according to commercial protocol.

Key findings

Pain assessment using mechanical (Von Frey) or thermal (Hot-Plate) nociceptive showed hyperalgesia from 2 weeks until 10 weeks progressively that was exacerbated following Ag, Cu and Al NPs intoxication in nerve lesioned groups.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2023

Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease.

Alzheimer's research & therapy · 2023

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

For this purpose, we studied changes in neuroprotective proteins proBDNF, BDNF, and humanin in plasma NDEVs from patients with mild to moderate AD participating in the randomized controlled trial (RCT) of exercise ADEX.

Study design

proBDNF, BDNF, and humanin were quantified in NDEVs immunocaptured from the plasma of 95 ADEX participants, randomized into exercise and control groups, and collected at baseline and 16 weeks.

Participants or experimental system

We studied all remaining 162 plasma samples from the ADEX cohort, sourced from 47 participants in the control group (n = 38 at baseline, n = 43 at 16 weeks), and 48 participants in the exercise group (n = 44 at baseline, n = 37 at 16 weeks).

Study scale

Not reported in the declared source.

Intervention or exposure

10 µL of intact EVs were stored at − 80 °C for nanoparticle tracking analysis (NTA) and the remaining volume was subjected to EV lysis via two freeze–thaw cycles in 25 µL of 10% bovine serum albumin and 365 µL of 1X RIPA lysis buffer (stock solution at 10X; cat. no. 20–188; EMD Millipore Corp.) supplemented with 1X protease/phosphatase inhibitors.

Comparator

Not reported in the declared source.

Outcomes examined

Exploratorily, we also quantified NDEV levels of putative exerkines known to respond to exercise in peripheral tissues.

Key findings

NDEV levels of proBDNF, BDNF, and humanin increased in the exercise group, especially in APOE ε4 carriers, but remained unchanged in the control group.

Limitations and uncertainty

Nevertheless, intrinsic generalizability constraints limit the relevance of our results to patients with mild to moderate AD.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Thymosin β4 and prothymosin α promote cardiac regeneration post-ischaemic injury in mice.

Cardiovascular research · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Here, we demonstrate increased 5-ethynyl-2’deoxyuridine incorporation in cardiomyocytes 3 days post-myocardial infarction in mice.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2023

The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.

The journal of headache and pain · 2023

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Our objective was to determine whether Lu AG09222, an investigational humanized monoclonal antibody directed against PACAP ligand, would inhibit the PACAP-signaling cascade by abolishing its vasodilatory and headache-inducing abilities.

Study design

In a randomized, double-blind, parallel-group, single-dose, placebo-controlled study of Lu AG09222, healthy volunteers aged 18–45 years without history of headache disorders were randomly allocated to three treatment sequences (1:2:2) on two experimental infusion visits with 9 ± 3 days’ interval: placebo + saline + saline (n = 5), placebo + PACAP38 + VIP (n = 10), and Lu AG09222 + PACAP38 + VIP (n = 10).

Participants or experimental system

All randomized participants who received either placebo or Lu AG09222 were included in the safety analysis; all participants who received an infusion of PACAP38 or saline and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-PACAP38 measurement on visit 1 were included in analyses related to the PACAP38 infusion; and all participants who received a VIP or saline infusion and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-VIP measurement on visit 2 were included in analyses related to the VIP infusion.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

This was a phase 1, interventional, randomized, double-blind, parallel-group, placebo-controlled, single-dose study investigating the effect of Lu AG09222 in a headache model with healthy volunteers.

Outcomes examined

Vascular parameters (superficial temporal artery [STA] diameter and radial artery [RA] diameter measured by high-resolution ultrasonography; facial flushing measured by speckle contrast imager), heart rate and headache were documented before Lu AG09222 or placebo infusion and PACAP38 or saline infusion at visit 1 and before VIP or saline infusion at visit 2.

Key findings

In participants who received Lu AG09222 + PACAP38 infusion, there was a significantly lower STA diameter (mean (SE) [95% CI] AUC ‒35.4 (4.32) [‒44.6, ‒26.3] mm × min; P < 0.0001) compared to participants who received placebo + PACAP38 infusion.

Limitations and uncertainty

This study has a relatively small sample size.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2023

Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial

Frontiers in neuroscience · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

We hypothesized that one potential approach to improve outcomes in traumatic brain injury (TBI) patients is combining Cerebrolysin treatment with repetitive transcranial magnetic stimulation (rTMS).

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2022

Systems spatiotemporal dynamics of traumatic brain injury at single-cell resolution reveals humanin as a therapeutic target.

Cellular and molecular life sciences : CMLS · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Our results offer a systems-level understanding of the dynamic and spatial regulation of gene programs by mTBI and pinpoint key target genes, pathways, and cell circuits that are amenable to therapeutics.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2022

The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment.

Frontiers in pharmacology · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Cell viability was measured using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2022

Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes.

Pakistan journal of medical sciences · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

In this retrospective study 120 patients who were admitted to North China University of Science and Technology Affiliated Hospital between January 2017 and January 2018 due to PTB complicated with diabetes were included according to the random sampling principle, and divided into two groups by random number table method, namely the Tα1 group (n=60) and the control group (n=60).

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2022

Role of VPAC1 and VPAC2 receptors in the etiology of pregnancy rhinitis: an experimental study in rats.

Brazilian journal of otorhinolaryngology · 2022

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

VPAC1 and VPAC2 were found to be in all layers of septal specimens, but the immunostaining of surface epithelium was more distinct in specimens of both groups.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2022

Histochemical Characterization of the Dorsal Raphe-Periaqueductal Grey Dopamine Transporter Neurons Projecting to the Extended Amygdala.

eNeuro · 2022

Study scale: C57BL/6 (n = 10), DAT-ires-cre (n = 4), DAT-ires-Cre::Ai14 (n = 17), and VGlut2-ires-Cre::Ai14 (n = 9) were used in this study.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

To identify putative DA neurons, DAT-Cre::Ai14 mice were used.

Study scale

C57BL/6 (n = 10), DAT-ires-cre (n = 4), DAT-ires-Cre::Ai14 (n = 17), and VGlut2-ires-Cre::Ai14 (n = 9) were used in this study.

Intervention or exposure

AAV5-EF1α-DIO-hChR2-EYFP (200 nl; catalog #20298-AAV5, Addgene, MA, USA) was injected into the DR-PAG region (in mm; AP: −4.3, ML: +1.0, from bregma; DV: −2.7 angled at 22°, from the brain surface) using a microinjector (Nanoject II, Drummond Scientific Company, PA, USA).

Comparator

Not reported in the declared source.

Outcomes examined

First, we examined the expression of DAT in the DR-PAG region (DATDR-PAG), depending on the expression of tdTomato of DAT-cre::Ai14 mice.

Key findings

It was observed that DATDR-PAG neurons consisted of the following two subpopulations: TH+/VIP– and TH–/VIP+ neurons.

Limitations and uncertainty

Therefore, in the present study, we aimed to clarify the potential heterogeneity of DADR-PAG neurons projecting to the CeA and BNST.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2022

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

Critical care medicine · 2022

Study scale: In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.

Study design

A multicenter, placebo-controlled trial.

Participants or experimental system

A total of 196 patients with COVID-19 respiratory failure.

Study scale

In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.

Intervention or exposure

Not reported in the declared source.

Comparator

Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.

Outcomes examined

The key secondary end point was survival at 60-day posttreatment, as ascertained by study-site personnel.

Key findings

There was, however, a statistically significant two-fold odds of improved survival (OR, 2.0; 95% CI, 1.1–3.9) at 60 days (p = 0.035).

Limitations and uncertainty

Another limitation was the randomization imbalance in baseline ventilation status as determined by the NIAID score.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked